Sickle cell disease (SCD) is caused by a mutation in the β-globin gene leading to polymerization of the sickle hemoglobin (HbS) and deformation of red blood cells. Autologous transplantation of hematopoietic stem/progenitor cells (HSPCs) genetically modified using lentiviral vectors (LVs) to express an anti-sickling β-globin leads to some clinical benefit in SCD patients, but it requires high-level transgene expression (i.e., high vector copy number [VCN]) to counteract HbS polymerization. Here, we developed therapeutic approaches combining LV-based gene addition and CRISPR-Cas9 strategies aimed to either knock down the sickle β-globin and increase the incorporation of an anti-sickling globin (AS3) in hemoglobin tetramers, or to induce the expression of anti-sickling fetal γ-globins. HSPCs from SCD patients were transduced with LVs expressing AS3 and a guide RNA either targeting the endogenous β-globin gene or regions involved in fetal hemoglobin silencing. Transfection of transduced cells with Cas9 protein resulted in high editing efficiency, elevated levels of anti-sickling hemoglobins, and rescue of the SCD phenotype at a significantly lower VCN compared to the conventional LV-based approach. This versatile platform can improve the efficacy of current gene addition approaches by combining different therapeutic strategies, thus reducing the vector amount required to achieve a therapeutic VCN and the associated genotoxicity risk.

Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease / Ramadier, S.; Chalumeau, A.; Felix, T.; Othman, N.; Aknoun, S.; Casini, A.; Maule, G.; Masson, C.; De Cian, A.; Frati, G.; Brusson, M.; Concordet, J. -P.; Cavazzana, M.; Cereseto, A.; El Nemer, W.; Amendola, M.; Wattellier, B.; Meneghini, V.; Miccio, A.. - In: MOLECULAR THERAPY. - ISSN 1525-0016. - 30:1(2022), pp. 145-163. [10.1016/j.ymthe.2021.08.019]

Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease

Casini A.;Maule G.;Cereseto A.;Amendola M.;
2022-01-01

Abstract

Sickle cell disease (SCD) is caused by a mutation in the β-globin gene leading to polymerization of the sickle hemoglobin (HbS) and deformation of red blood cells. Autologous transplantation of hematopoietic stem/progenitor cells (HSPCs) genetically modified using lentiviral vectors (LVs) to express an anti-sickling β-globin leads to some clinical benefit in SCD patients, but it requires high-level transgene expression (i.e., high vector copy number [VCN]) to counteract HbS polymerization. Here, we developed therapeutic approaches combining LV-based gene addition and CRISPR-Cas9 strategies aimed to either knock down the sickle β-globin and increase the incorporation of an anti-sickling globin (AS3) in hemoglobin tetramers, or to induce the expression of anti-sickling fetal γ-globins. HSPCs from SCD patients were transduced with LVs expressing AS3 and a guide RNA either targeting the endogenous β-globin gene or regions involved in fetal hemoglobin silencing. Transfection of transduced cells with Cas9 protein resulted in high editing efficiency, elevated levels of anti-sickling hemoglobins, and rescue of the SCD phenotype at a significantly lower VCN compared to the conventional LV-based approach. This versatile platform can improve the efficacy of current gene addition approaches by combining different therapeutic strategies, thus reducing the vector amount required to achieve a therapeutic VCN and the associated genotoxicity risk.
2022
1
Ramadier, S.; Chalumeau, A.; Felix, T.; Othman, N.; Aknoun, S.; Casini, A.; Maule, G.; Masson, C.; De Cian, A.; Frati, G.; Brusson, M.; Concordet, J. ...espandi
Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease / Ramadier, S.; Chalumeau, A.; Felix, T.; Othman, N.; Aknoun, S.; Casini, A.; Maule, G.; Masson, C.; De Cian, A.; Frati, G.; Brusson, M.; Concordet, J. -P.; Cavazzana, M.; Cereseto, A.; El Nemer, W.; Amendola, M.; Wattellier, B.; Meneghini, V.; Miccio, A.. - In: MOLECULAR THERAPY. - ISSN 1525-0016. - 30:1(2022), pp. 145-163. [10.1016/j.ymthe.2021.08.019]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/327038
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact